Good morning, and welcome to Johnson & Johnson's Fourth Quarter 2023 Earnings Conference Call. All participants will be in a listen-only mode until the question-and-answer session. This call is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the call over to Johnson & Johnson. You may begin.

Good morning. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of business results for the fourth quarter and full year 2023 and our financial outlook for 2024. Joining me on today's call are Joaquin Duato, Chairman and Chief Executive Officer; and Joe Wolk, Executive Vice President, Chief Financial Officer. As a reminder, you can find additional materials including today's presentation and associated schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and business strategy. You are cautioned not to rely on these forward-looking statements, which are based on current expectations of future events using the information available as of the date of this recording, and are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. A description of these risks, uncertainties and other factors can be found in our SEC filings, including our 2022 Form 10-K, which is available at investor.jnj.com and on the SEC's website. Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda. Joaquin will open with a few comments on our 2023 performance and key milestones, as well as highlights from our Enterprise Business Review. I will then review the fourth quarter sales and P&L results as well as full year 2023 results for the Enterprise. Joe will then close by sharing an overview of our cash position, capital allocation priorities, and guidance for 2024. The remaining time will be available for your questions. To ensure we provide enough time to address your questions, we anticipate the webcast will last a little over 60 minutes. I'm now pleased to turn the call over to Joaquin.

Thank you, Jess, and good morning, everyone. 2023 was a remarkable year for Johnson & Johnson in becoming a two-sector company focused on innovative medicine at MedTech, we strengthened our position as an innovation powerhouse. We breakthrough science and transformative technology, we innovate across the entire patient pathway in ways no other company can. And as we shared at our Enterprise Business Review, we have a stronger growth margin profile and are more focused and agile than ever before, which is what you see with today's results. I'm particularly proud of our Q4 results with innovative medicine operational sales, excluding the COVID-19 vaccine, growing by 9.5% at MedTech adjusted operational sales growing by an impressive 9.1%. For the full year, we delivered strong and sustained performance with 9% operational sales growth excluding the COVID-19 vaccine and 10.8% adjusted operational earnings per share growth. These results reflect the breadth and competitiveness of our portfolio. And when I look at the milestones we achieved in 2023 and the promise of our pipeline, I have confidence in our guidance for 2024 and beyond. So let's take a deeper look at the business and what we achieved last year. Starting with Innovative Medicine. For the full year, we delivered above-market operational sales growth of 7.2%, excluding the COVID-19 vaccine. Our Innovative Medicine business continues to be fueled by growth from key brands and the acceleration of sales of new products. Our multiple myeloma portfolio is a good example with significant contributions from recently launched products including CARVYKTI, TECVAYLI, and TALVEY. Turning to clinical trials. Key results from the year included positive Phase III readouts for more than 10 of our in-line and pipeline medicines, including CARVYKTI, in one to three prior lines of therapy in multiple myeloma. DARZALEX in front-line multi myeloma transplant-eligible patients. RYBREVANT, in combination with chemotherapy and RYBREVANT plus lazertinib in non-small cell lung cancer. And finally TREMFYA monotherapy in Ulcerative Colitis. In addition, we saw positive Phase 1 and Phase 2 readouts for nipocalimab and TAR-200 and TAR-210 and we initiated our Phase 3 clinical development programs for Milvexian and our targeted oral peptide JNJ-2113. Beyond that, we received FDA breakthrough designation for TAR-200 for the treatment of bladder cancer and fast track designations for Milvexian in Atrial Fibrillation, Stroke, and Acute Coronary Syndrome. And with 19 U.S. and EU filings across our Innovative Medicine business in 2023, we have high expectations for the year ahead. Our recent announcement of a definitive agreement to acquire Ambrx to develop next-generation antibody drug conjugates further strengthens our oncology pipeline. Now moving to MedTech. In 2023, we delivered full-year operational sales growth of 12.4% and full-year adjusted operational sales growth of 7.8%. For the first time, our MedTech team delivered more than $30 billion in sales, as we continue to build a best-in-class business. We are accelerating growth through commercial execution, differentiated innovation and moving into higher growth markets, as you saw with our successful integration of Abiomed and our recent acquisition of Laminar, which focused on eliminating the left atrial appendage in patients with non-valvular atrial fibrillation. And at the same time, we are making strong progress in our pipeline, including advancing our Ottava surgical robot, MONARCH approval in China for bronchoscopy and continued market expansion for VELYS, our robotic-assisted solution for total knee replacement with CE Mark approval in 2023. In electrophysiology, we have a lot of momentum in our post-field ablation portfolio. We announced regulatory approval a few weeks ago for the VARIPULSE PFA platform in Japan and have submitted for CE Mark approval in the EU. The true pulse generator has received approval in the EU and we received the first and only approval from the U.S. FDA for a zero fluoroscopy workflow for cardiac ablation. And in the fourth quarter, findings from our QDOT MICRO Catheter Q-FFICIENCY Study showed that very high-power, short-duration ablations improved quality of life and reduced healthcare utilization for atrial fibrillation patients. In Vision, we are driving strong performance across our TECNIS IOLs and OASYS 1-day family of contact lenses, including our most premium lens, ACUVUE OASYS MAX 1-Day, which has proven superiority in comfort and clarity versus the competition. Turning to Abiomed. We recently completed our Impella ECP pivotal clinical trial. In Q4, we also enrolled our first patient in the Abiomed RECOVER IV randomized, controlled trial. As we look ahead, I have never been more excited about the future of our business. At our Enterprise Business Review, we shared that we expect our Innovative Medicine business to grow 5% to 7% from 2025 to 2030 with our industry-leading pipeline and portfolio delivering more than 10 assets that have the potential to generate over $5 billion in peak year sales by 2030. We also expect a further 15 assets to have the potential for $1 billion to $5 billion in peak year sales. In 2024, we expect data readouts for many of these assets, including Phase 3 trials for TREMFYA in IBD, ERLEADA in heavy-stage prostate cancer, our targeted oral peptide JNJ-2113 in psoriasis, Nipocalimab in Myasthenia Gravis as well as aticaprant and seltorexant in major depressive disorder. We also expect Phase 2 readouts for our combination therapy, guselkumab and golimumab, JNJ-4804 in psoriatic arthritis, nipocalimab in Sjogren's Disease and TAR-200 in non-muscle invasive bladder cancer. In MedTech, we shared that we expect to grow at the upper range of our markets, which are anticipated to grow by 5% to 7% between 2022 and 2027. And that by 2027, we expect one-third of our revenue to be generated by new products. In 2024, we see strong progress towards these goals. In electrophysiology, that includes the full U.S. market release of QDOT MICRO Catheter and we are expecting CE Mark approval for our post-field ablation catheter VARIPULSE in Europe in the first half of 2024. We plan to submit an investigational device exemption to the FDA for Ottava in the second half of 2024. And in Abiomed, we expect the U.S. commercial launch of Impella RP Flex with smart assist and an Impella ECP submission in 2024. As you can see, our pipeline is advancing. Our business is transforming. Before I turn the call to Jess and Joe, I want to thank our teams around the world for everything they do to help our patients. We have entered 2024 from a position of strength, and I'm confident in our ability to lead the next wave of health innovation. With that, I'll turn the call over to Jess.

Thanks, Joaquin. Unless otherwise stated, the financial results and guidance highlighted reflects the continuing operations of Johnson & Johnson. We will report the consumer health financial results as discontinued operations. Furthermore, the percentages quoted represent operational results and therefore, exclude the impact of currency translation. Starting with Q4 2023 sales results. Worldwide sales were $21.4 billion for the fourth quarter of 2023. Sales increased 7.2%, with 11% in the U.S. and 2.7% outside of the U.S. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 5.7% worldwide, 8.8% in the U.S. and 2.1% outside the U.S. It is important to note that sales in Europe were negatively impacted by the COVID-19 vaccine and the loss of exclusivity of ZYTIGA by approximately 1,500 basis points operationally. Turning now to earnings. For the quarter, net earnings were $4.1 billion, and diluted earnings per share was $1.70 versus diluted earnings per share of $1.22 a year ago. Excluding after-tax intangible asset amortization expense and special items for both periods, adjusted net earnings for the quarter were $5.6 billion and the diluted earnings per share was $2.29, representing increases of 2.4% and 11.7%, respectively, compared to the fourth quarter of 2022. On an operational basis, adjusted diluted earnings per share increased 11.2%. For the full year 2023, sales were $85.2 billion. Sales grew 7.4%, with 10.6% in the U.S. and 3.8% outside of the U.S. Excluding the net impact of acquisitions and divestitures, adjusted operational sales growth was 5.9% worldwide, 8.2% in the U.S. and 3.4% outside the U.S. Sales in Europe were negatively impacted by the COVID-19 vaccine and loss of exclusivity of ZYTIGA by approximately 1,000 basis points operationally. Net earnings for the full year 2023 were $13.3 billion and diluted earnings per share was $5.20 versus diluted earnings per share of $6.14 a year ago. Full year 2023 adjusted net earnings were $25.4 billion, and adjusted diluted earnings per share was $9.92, representing increases of 6.8% and 11.1%, respectively, versus full year 2022. On an operational basis, adjusted diluted earnings per share increased by 10.8%. I will now comment on business sales performance in the quarter. Beginning with Innovative Medicine. Worldwide Innovative Medicine sales of $13.7 billion increased 4% with growth of 9.5% in the U.S. and a decline of 3.1% outside of the U.S. Excluding COVID-19 vaccine sales, worldwide and U.S. sales growth was 9.5%, and growth outside the U.S. was 9.4%. Sales outside the U.S., excluding the COVID-19 vaccine, were negatively impacted by approximately 120 basis points due to the loss of exclusivity of ZYTIGA in Europe. Innovative Medicine growth was driven by our key brands and the continued uptake from recently launched products, with nine assets delivering double-digit growth. We continue to drive strong sales growth for both DARZALEX and ERLEADA, with increases of 22.2% and 19%, respectively. Within immunology, we saw sales growth in both STELARA and TREMFYA, with increases of 14.5% and 20.5%, respectively. This growth was driven by market growth and share gains as well as a favorable patient mix in TREMFYA. Growth of 17.4% in pulmonary hypertension was driven by favorable patient mix, share gains, and market growth. Turning to newly launched products. We continue to make progress on our launches of CARVYKTI and SPRAVATO. We are also encouraged by the early success of our launches of TECVAYLI and TALVEY, sales of which are driving the growth in other Oncology. As a reminder, we expect to begin disclosing TECVAYLI sales in Q1 2024. Total Innovative Medicine sales growth was partially offset by unfavorable patient mix in XARELTO, a decrease in IMBRUVICA sales due to competitive pressures and the loss of exclusivity of ZYTIGA, REMICADE, and PREZISTA. I'll now turn your attention to MedTech. Worldwide MedTech sales of $7.7 billion increased 13.4% with Abiomed contributing 4.5% to growth. Growth in the U.S. was 14.1% and 12.8% outside of the U.S. Excluding the impact of acquisitions and divestitures, worldwide adjusted operational sales growth was 9.1%. MedTech was negatively impacted by international sanctions in Russia worth approximately 50 basis points, primarily in Advanced Surgery and Vision. Electrophysiology delivered double-digit growth of 25.2% with strong growth in all regions, including Europe. This growth was driven by our global market-leading portfolio, including the most recently launched QDOT RF ablation and OCTARAY catheters. Abiomed contributed $340 million in sales within the quarter driven by continued strong adoption of Impella 5.5 technology. Growth of 6.4% in surgery was driven primarily by procedure recovery and strength of our biosurgery and wound closure portfolios. Growth was partially offset by volume-based procurement in China, primarily in Endocutters. Orthopaedics growth of 5% reflects procedure growth, success of recently launched products such as the global expansion of our VELYS digital solutions and expansion in ambulatory surgical centers, as well as lapping of prior year China’s VBP price concessions in Spine. Growth of 6.6% in Vision was driven by price actions and contact lenses, as well as the strength of new products including ACUVUE OASYS 1-Day family of products and contact lenses and TECNIS EYHANCE, our monofocal interocular lens and surgical vision. Growth of contact lenses was partially offset by U.S. stocking dynamics. Global Vision growth was negatively impacted by 140 basis points due to the Blink divestiture in Q3. Now turning to our consolidated statement of earnings for the fourth quarter of 2023. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year. Cost of products sold margin deleveraged by 130 basis points due to commodity inflation and unfavorable product mix in MedTech, partially offset by favorable patient mix and lower COVID-19 vaccine supply network related exit cost in Innovative Medicine. We continue to invest strategically in research and development at competitive levels, investing $4.5 billion or 20.9% of sales this quarter. We invested $3.4 billion or 24.5% of sales in Innovative Medicine with the increase in investment being driven by higher milestones, partially offset by portfolio prioritization. In MedTech, R&D investment was $1.1 billion or 14.6% of sales with the increase in investment primarily driven by the Laminar acquisition. Interest income was $212 million in the fourth quarter of 2023 as compared to $77 million of income in the fourth quarter of 2022. The increase in income was driven by higher interest rates earned on cash balances and a lower average debt balance. The other income and expense line was income of $421 million in the fourth quarter of 2023 compared to an expense of $795 million in the fourth quarter of 2022. This was primarily driven by higher unrealized gains on securities and lower COVID-19 vaccine-related exit costs. Regarding taxes in the quarter, our effective tax rate was 14.4% versus 16% in the same period last year. This decrease was primarily driven by the net decrease of tax liabilities, including the settlement of the 2013 through 2016 U.S. tax audit. Excluding special items, the effective tax rate was 10.8% versus 16.2% in the same period last year. I encourage you to review our upcoming 2023 10-K filing for additional details on specific tax-related matters. Lastly, I will direct your attention to the box section of the slide, where we have also provided our income before tax, net earnings and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. Now let's look at adjusted income before tax by segment. In the fourth quarter of 2023, our adjusted income before tax for the enterprise as a percentage of sales decreased from 32.5% to 29.2%. Innovative Medicine margins declined from 37.7% to 37.4%, primarily driven by higher R&D milestones, partially offset by favorable patient mix and leveraging selling and marketing expenses. MedTech margins declined from 24.5% to 15.5% primarily driven by in-process research and development expenses from the Laminar acquisition, commodity inflation, and unfavorable product mix, partially offset by selling and marketing expense leverage. This concludes the sale and earnings portion of the call. I'm now pleased to turn it over to Joe.

Thank you, Jessica, and thanks, everyone, for joining us today. As Joaquin and Jessica commented, 2023 was a strong year for Johnson & Johnson evidenced by notable top and bottom line performance beats relative to what we guided to 2023 at this time last year. We are particularly proud of the innovation we advanced to strengthen our development pipelines, the continued expansion of our portfolio, and investments made for future success. All of this provides us with a strong foundation as we enter 2024. Thus far during the call, you've heard about sales and income performance in 2023. So now let's dive into some detail on capital allocation highlights. We generated free cash flow of more than $18 billion in 2023. At the end of the year, we had approximately $23 billion of cash and marketable securities and approximately $29 billion of debt for a net debt position of $6 billion. We maintained a healthy balance sheet and robust credit rating, underscoring the strength of Johnson & Johnson's financial position, which enables us to strategically invest and deploy capital to unlock value. To that end, we executed against all of our capital allocation priorities in 2023. For starters, we invested more than $15 billion in research and development or 17.7% of sales, an all-time high for the company as we remain one of the top investors in R&D across all industries. Jessica provided R&D investment by business segment, information we will continue to provide on a quarterly basis moving forward. As far as dividends, 2023 marked the 61st consecutive year in which we increased our dividend. We know this use of capital is a priority for our investors, and we plan to continue to increase our dividend annually. We also deployed, announced, or committed over $3 billion in strategic, value-creating inorganic growth opportunities in the last 12 months. This amount includes the recent Ambrx and Laminar transactions as well as more than 50 smaller early-stage licensing deals and partnerships that complement our current Innovative Medicine and MedTech pipelines. Finally, share repurchases. In early 2023, we completed the $5 billion share repurchase program initiated in late 2022 and in combination with our dividend, returned over $14 billion to shareholders last year. Through the Kenvue separation, we further reduced the Johnson & Johnson's outstanding share count by 191 million shares or approximately 7% without the use of cash and in a tax-free manner. Looking ahead to 2024, Johnson & Johnson's robust free cash flow generation should continue to solidify our already strong financial foundation and fuel further investment leading to growth for our business or returns to shareholders. Now turning to our full-year 2024 guidance. Today, we are confirming the 2024 guidance for those items previewed at our enterprise business review in early December by filling in some of the details. We expect operational sales growth for the full year to be in the range of 5% to 6% or $88.2 billion to $89 billion. As a reminder, our sales guidance continues to exclude any impact from COVID-19 vaccine sales. In Innovative Medicine, we expect 2024 to deliver a 13th consecutive year of above-market growth, driven by market share gains from key brands such as DARZALEX, TREMFYA, and ERLEADA as well as continued adoption of recently launched newer products such as CARVYKTI, TECVAYLI, TALVEY, and SPRAVATO. In MedTech, we remain focused on executing our key value drivers: first, advancing our differentiated pipeline such as programs in pulse field ablation, Abiomed, and surgical robotics, further shifting our portfolio into high-growth markets; second, expanding our reach and scale around the world; and third, building operational resilience across our portfolio. We don't speculate on future currency movements, but utilizing the euro spot rate relative to the U.S. dollar as of last week at $1.09 as well as other major currencies, we estimate there would be a slight unfavorable impact of $400 million or a negative 0.5% on reported sales growth for the year. Turning to other items on our P&L, we expect our adjusted pretax operating margin to improve by approximately 50 basis points driven primarily by a continuation of efficiency programs across the organization. We expect this to be partially offset by anticipated STELARA biosimilar entrants in Europe in the second half of this year and some lingering inflation impact in MedTech inventory that will flow through 2024's P&L. This margin improvement encompasses dilution of additional investment associated with our planned acquisition of Ambrx, which will be treated as a business combination. Now we do acknowledge that this 50 basis point improvement simply gets us back to what your models expected, given the elevated Q4 2023 R&D investment for new pipeline assets. Regarding other income and expense, we anticipate income to be $1.2 billion to $1.4 billion for 2024. This is less than the 2023 amount driven by the impact of actuarial assumptions on certain employee benefit programs such as lower discount rates. We are comfortable with you modeling net interest income between $450 million and $550 million, consistent with 2023 levels. Finally, we are projecting an effective tax rate for 2024 in the range of 16% to 17% based on current tax laws and anticipated geographic income mix across our businesses. This tax rate takes into account an increase of approximately 1.5% or 150 basis points relative to the recently enacted Pillar 2 legislation. We continue to believe the U.S. Treasury's current perspective on Pillar 2 is harmful, reducing U.S. incentives for innovation and resulting in U.S.-based multinational companies paying more tax revenue to foreign governments. Our full-year share count calculation for adjusted earnings per share in 2024 will include the remaining benefit equal to approximately 120 million shares from the approximately 191 million net share reduction in outstanding J&J shares following the Kenvue exchange offer. Given all these factors, we expect adjusted operational earnings per share to grow 7.4% at the midpoint for a range of $10.55 to $10.75. Based on the euro spot rate of 1.09 from last week, we do not estimate any currency impact on earnings per share. I'll now provide some qualitative considerations on quarterly phasing for your models. We expect Innovative Medicine sales growth to be slightly stronger in the first half of the year compared to the second half, given the anticipated entry of STELARA biosimilars in Europe towards the middle of the year. This headwind will be partially offset by continued uptake from our recently launched products. We project MedTech operational sales growth to be relatively consistent throughout the year, expecting procedures in 2024 to remain above pre-COVID levels. The first half of the year will continue to have a modest impact from Russia sanctions as our licenses are approved. We anticipate China VBP pricing for surgical IOLs and orthopedic sports to begin in 2024 with impacts from 2023 VBP in electrophysiology, Endocutters, Energy, Spine, and Trauma to begin to anniversary throughout 2024. Regarding EPS phasing, it is important to highlight that the first half of the year will benefit from the full 191 million net share reduction following the Kenvue exchange offer with only a partial comparative benefit in the third quarter versus Q3 2023 and the fourth quarter being neutral versus Q4 2023. So based on the foundation strengthened in 2023 and numerous catalysts that Joaquin outlined across our business in 2024, we are confident in our ability to achieve both near and long-term financial targets. I'd like to close by thanking our colleagues for their dedication and commitment to benefit patients around the world. It is their effort that enables Johnson & Johnson to deliver innovative therapies and solutions that address serious unmet medical needs and creates long-term sustainable value for shareholders. With that, I’m now pleased to turn the call over to Kevin to begin the Q&A portion of the call.

Thank you. Our first question today is coming from Joanne Wuensch from Citi. Your line is now live.

Good morning, and thank you for taking the questions. With my one question, I'm curious why you're looking for 2024 procedure volumes to remain above pre-COVID levels and your expectations for how long that will last? Thank you.

Thank you, Joanne, and good morning, everyone. First, I want to highlight the strong performance of our MedTech business in 2023. We achieved over $30 billion in annual sales, marking an all-time high for our company, with an operational adjusted growth rate of 9.1% in the fourth quarter. We saw impressive results across various sectors, including electrophysiology, heart recovery, surgery, orthopedics, and Vision. Looking back at our results from 2023, we believe they align with our competitors for the year, but we outperformed them in the fourth quarter. The global impacts of COVID-19 have stabilized, and although we are still facing some macro challenges like inflation and hospital staffing, there is a surge of patients entering the market post-COVID-19, resulting in market growth for 2023 that exceeds historical averages. We anticipate this trend to continue well into 2024, serving as a tailwind for us. Several factors contribute to this outlook, including ongoing procedures that we expect to continue into at least the first half of 2024. Furthermore, we have several advantages aside from the procedural growth that give me confidence about 2024. Our heart recovery sector, particularly with the adoption of Impella 5.5, is progressing strongly. We have already filed for our Impella ECP, which is a smaller variant of Impella CP. In orthopedics, we are advancing into high-growth markets with our VELYS Robotic-Assisted Solution and have received CE Mark approval in Europe. In the surgery segment, we are launching innovations such as the [indiscernible], Energy, and ECHELON 3000 stapler, along with expanding our Plus Sutures. In our Vision sector, we're extending our TECNIS family into the premium segment of intraocular lenses. Additionally, in electrophysiology, we are broadening our PFA catheter portfolio. Earlier this year, we received approval for our VARIPULSE loop catheter in Japan and are actively rolling out our latest radio frequency ablation catheter, QDOT MICRO, globally. Overall, there are numerous catalysts and tailwinds supporting our MedTech business heading into 2024. As we highlighted in our Enterprise Business Review, we expect our MedTech division to grow at the leading edge of our markets, positioning us as a top competitor in the MedTech field.

Thank you. Next question is coming from Terence Flynn from Morgan Stanley. Your line is now live.

Great. Thanks so much for taking the question. Maybe two-part for me on CARVYKTI. I noticed an ODAC panel was just announced to review the CARTITUDE-4 data. I was just wondering if you can talk about the focus of that upcoming meeting and your confidence in an on-time label expansion for CARTITUDE-4? And then the second part of the question is I know in manufacturing, you've been ramping up in Belgium, and I believe that facility is now up and running. So how should we think about supply for 2024 broadly for CARVYKTI? Thank you.

Thank you, Terence. So with more than 2,000 patients treated CARVYKTI, it's already the fastest launch CAR-T in the market overall and we are pleased to continue to see quarter-over-quarter sequential growth in CARVYKTI. And overall, we remain confident in two things, both the risk-benefit of CARVYKTI in the indication that is being studied and at the same time on the potential of CARVYKTI to be a $5 billion plus asset at peak year sales. Regarding the ODAC that you commented on, we are very confident on the data of our Phase 3 CARTITUDE-4 study that as a reminder, support the efficacy and safety of CARVYKTI in one to three prior lines in the treatment of patients with relapsed/refractory multiple myeloma. We presented the results at ASCO, as you know, and we also published those results in the New England Journal of Medicine. And we very much look forward to reviewing the updated survival and safety data with the FDA ODAC in the future. We are committed to working with the FDA in the continued development of CARVYKTI, and we continue to have the focus on bringing this immunotherapy to multiple myeloma patients in earlier lines of therapy. We are working with the FDA towards a PDUFA date for our CARTITUDE-4 indication in April 5, and with EMEA towards an anticipated CHMP opinion in the first quarter of 2024. So overall, we feel confident about the risk-benefit profile in this indication and about the future of CARVYKTI. Regarding your manufacturing question, we've done significant progress in our manufacturing capacity, which is a major driver in the continuous growth of CARVYKTI. On the cell processing side, we have doubled our cell processing capacity in our Raritan facility. Since 2023. We are making progress to your point, Terence, in our European cell processing facilities. We are already manufacturing the first batches of CARVYKTI for clinical use this month of January. And we also have contracted additional capacity, external capacity to scale up production and increase our ability moving forward that will start mid this year. On the other hand, we have also made significant progress in the internalization and scale-up of our lentivirus production. We have increased capacity in Switzerland, in our Switzerland facility. And at the same time, we continue to progress with new U.S. capacity and additions site in the Netherlands to produce our lentivirus. Late December, we received approval to expand our lentivirus capacity from 20-liter tanks to 50-liter tanks of lentivirus production in our U.S. facility. So overall, we feel good that we are progressing with CARVYKTI that we will continue to deliver quarter-over-quarter growth in 2024. And we are working towards building this $5 billion plus product and continue to transform the treatment paradigm in multiple myeloma, as we have discussed in the past, moving from treating to progression to treating to cure as we move CARVYKTI into earlier lines of therapy.

Thank you. Next question is coming from Larry Biegelsen from Wells Fargo. Your line is now live.

Good morning. Thank you for taking my question. Congratulations on a strong finish to the year. Joe or Joaquin, could you provide a general update on your M&A interest and elaborate on your recent comments about Abiomed serving as a gateway in cardiovascular devices, which you mentioned earlier this month? Thank you for addressing my question.

Yeah. So Larry, let me start, good morning, and then I can turn it over to Joaquin. So we are very well positioned to continue to entertain many types of deals. As you know, we have the parameters of making sure that they are a strategic fit so that we've got scientific expertise and insights, a familiarity with the space has proven to be our most successful platforms. We want to make sure that we're earning a fair return to compensate shareholders for the risk that we're bearing on their behalf. It was only 13 months ago, we were able to deploy $17 billion in capital for Abiomed. We're very pleased with that acquisition. Not only has it beat our internal deal models, but it also is performing better than what the Street had called for that business prior to the announcement of the acquisition. So it's been a really nice fit. What I would say is, we also deployed or announced, as I said in my prepared remarks, over $3 billion in capital for more than 50 smaller licensing partnerships or deals. And while those may not have made headlines, they usually are headlines when they become products for patients. And so when you think about our history of DARZALEX, IMBRUVICA, CARVYKTI for one, that's been our track record. Our appetite is still, I would say, interested in moving into spaces that complement our existing portfolio, whether that be for the near or long term.

Thank you. And look, talking about that, Larry, let me say, we are agnostic to sector and agnostic to size. And as Joe commented, our preference is clearly to be in areas in which we have internal capabilities and know-how, and also to go into products that represent a significant progress from the point of view of improving the current standard of care and that are first-in-class and best-in-class. To illustrate that, the two deals that we completed this year, Laminar and Ambrx would be in that direction. So for example, Laminar is a deal in an area we know well, which is atrial fibrillation, and we believe could be first-in-class to be a device that can eliminate the left atrial appendage. When it comes to Ambrx, it's a deal in an area that we have a strong legacy like prostate cancer with a number of products marketed already. And this could be a first-in-class antibody drug conjugate in order to address a significant medical need in metastatic cut-resistant prostate cancer in patients that have failed under gene therapy. So very much so, and in that context, we continue to see also opportunities when it comes to Innovative Medicine in neuroscience and in immunology. And when it comes to MedTech, to your point, in other cardiology areas based on the strength that we have now with Biosense Webster and Abiomed and not excluding also the potential for other areas like robotic surgery or segments of orthopedics that are growing faster and also areas of Vision. So overall, that’s our approach. We try to put this strategic, scientific lens in order to be able to deliver value for patients and also value for our shareholders.

Thank you. Next question is coming from Chris Schott from JPMorgan. Your line is now live.

Thank you. Joe, I have a question for you. How should we view gross margins in 2024 and beyond? I understand you mentioned operating margins, but it appears that adjusted gross margins declined in Q4. I'm curious if this is a one-time occurrence or indicative of a longer-term trend as we consider the progression of your P&L over the next few years. Thank you.

Yeah. Good morning, Chris. Thanks for the question. I think as you look at that specifically for the fourth quarter, what you have in our operating margins is obviously the Laminar transaction that was part of that mix. So on our slide that details IBT, you likely saw a quarterly reduction in MedTech, specifically of about 9 points, about 2 points for the full year. I would say two-thirds of that is represented by the Laminar transaction. You also then have, I would say, in the fourth quarter, specific some mix as orthopedics performed probably a little bit better than it had in previous quarters. And then you have the inflationary impact, obviously, with higher levels of inventory on our balance sheet that flow through the P&L that is occurring throughout 2023. And we expect it to occur throughout at least the first half of 2024. We're not seeing any incremental inflation in, I'll call it, current activity. So it's not being additive to inventory, but it's also not subsiding either. So we're kind of at a new, I'd say, water level, if you will, that should be going forward, but not hurting the P&L as we look out beyond the second half of 2024.

Thank you. Our next question today is coming from Shagun Singh from RBC Capital Markets. Your line is now live.

Great. Thank you so much. I was just wondering, if we could get your latest thoughts on the potential impact of Novo's osteoarthritis data on orthopedic utilization, given the focus on WOMAC or pain scores. I believe the presentation could be here soon. Just curious to hear your thoughts and also what kind of scores could or may not have a potential impact? Thank you for taking the question.

So overall, look, osteoarthritis is a contributor to knee surgery. Sometimes I'm asked about osteoarthritis in the context of the GLP-1s, and weight is not a factor in osteoarthritis. We continue to look at this data, and it's early for us to give you an answer there. Now what we can tell you is that we continue to see an increased volume of procedures in orthopedics based on coming out of COVID. And we don't see any change in that neither in the hips or in the knee area or in any of the segments that we compete. So we are optimistic about our orthopedics trajectory. Specifically, we are optimistic about how we are progressing with our VELYS robotic system for total knee replacement. We have already completed 30,000 procedures with very positive feedback from the surgeons, especially in the ambulatory surgical centers. We are working to submit our 510(k) for our VELYS unique knee application. And we are seeing a strong recovery also in our hip business with a combination of new products like ACTIS, KINCISE, and VELYS hip navigation. So we feel good about our orthopedics business as we continue to see global procedure recovery in most markets. We continue to succeed with our new products, and we also want to mention the headwind that we had in China during this year. So very positive outlook moving forward for our orthopedics business.

Shagun, it's important to remind everyone about our comments from last quarter regarding our focus on enhancing the profitability of the orthopedics unit. We are being very selective about which geographies we operate in and which SKUs we offer. Consequently, in addition to the strong performance in revenue that Joaquin mentioned, we expect to see improved margins for that business as well.

Thank you. Our next question today is coming from Vamil Divan from Guggenheim Securities. Your line is now live.

Great. Thanks so much for taking my questions. So just maybe an area we don't spend as much time on is on the respiratory side, specifically, PAH. But just sort of a two-part question, but that franchise of yours continues to sort of outperform expectations. So curious, if you can talk about sort of what's driving success there? There's also an area where you don't have a lot of sort of longer-term investment. So going back to sort of the business development question, I'm just curious in your interest in sort of PAH or respiratory more generally as an area, further focus given your key franchises are going to be going away, but you do have the infrastructure there already?

So first, let me underline the great results of our PAH franchise in 2023. We had growth in the high teens driven by improved patient mix, market growth coming out of COVID too. This was an area that was heavily impacted by COVID as pulmonologists were focused on COVID and not diagnosing new patients. So overall, it's been a very positive trajectory of our PAH business, and we remain confident about the short-term future of this business into 2024. We are working towards the combination of macitentan and OPSUMIT with Tadalafil, which the trademark will be OPSYNVI. And that would be another option for patients there to enhance compliance. In my talks with physicians treating pulmonary hypertension, they seem very positive about it, and we expect an approval of that combination in 2024. So that's the outlook for our pulmonary franchise. Are we looking at other areas there? Yes, we are looking at the space to see if there are potential opportunities to be able to improve the standard of care. We continue to look to see how we can extend the success of our pulmonary franchise into the future. But overall, we're very happy with the trajectory of our pulmonary franchise in 2023, and we expect a similar trajectory as macitentan, OPSUMIT, and Tadalafil become the standard of care clearly established in this area.

Thank you. Our next question today is coming from Louise Chen from Cantor Fitzgerald. Your line is now live.

Hi. Thank you for taking my question here. I just wanted to ask you with respect to your oncology franchise. Do you have any thoughts on CAR-Ts for autoimmune disease at all? And then secondly, radiopharmaceutical?

Thank you, Louise. We have a strong oncology portfolio across various areas. I previously mentioned our prostate cancer treatment ERLEADA. In 2024, we anticipate data related to high-risk localized prostate cancer with the addition of Ambrx and an antibody-drug conjugate. We are particularly excited about RYBREVANT and its combination with lazertinib. We have completed Phase 3 studies for this combination, have submitted applications for all three indications, and expect approval in 2024. We are very enthusiastic about RYBREVANT and its use in first-line treatment for EGFR-mutated non-small cell lung cancer. Regarding bladder cancer, we plan to share data from TARIS-200 and TARIS-210 in non-muscle invasive localized bladder cancer. In 2023, we received FDA breakthrough designation for TARIS-200. Our multiple myeloma portfolio is also progressing well; CARVYKTI shows impressive sales data in newly diagnosed, transplant-eligible patients. In response to your question, we are exploring CAR-T therapies for autoimmune diseases, but the data is still early. Earlier this year, we partnered on two CAR-Ts, one targeting CD19 and another a BiCAR targeting both CD19 and CD20. While it's early, the results appear promising. We are also interested in radiopharmaceuticals and believe our work with antibody-drug conjugates presents important therapeutic options. This year, we entered into a partnership with Nanobiotics for a radio enhancer still under development for head and neck cancer. At the end of the year, we expanded our rights, which could open up new opportunities by leveraging our expertise in medical devices, technology, and pharmaceuticals. We aim to develop a more comprehensive plan for our radio enhancing and will share more details as we progress. Overall, we are pleased with the advancements in our oncology portfolio, both in solid tumors and hematology, as it remains a core strength of our Innovative Medicine group.

Thank you. Our next question is coming from Matt Miksic from Barclays. Your line is now live.

Hi. Thanks so much for taking the question. I wanted to follow up on some of the comments you made about MedTech trends and margins. And I think you mentioned some of the headwinds there were patient mix. Would love to get an idea of maybe kind of in the middle of the P&L and the operating line in terms of margin progression throughout the year, which ones of those of your business lines being kind of more reflecting that negative mix that you described and how that progresses during the year? Thanks.

Yeah, Matt. I apologize, but it was a little tough to hear your question entirely. I think it was around margins, specifically in MedTech and how that may progress through the year. So as I stated earlier, I would say that the margin profile is going to be impacted by inflationary pressures that were incurred really in 2022, sit on our balance sheet as inventory and then kind of flow through the P&L throughout the corresponding 2023 and probably a good piece of 2024. That being said, Tim and the team are doing magnificent work in terms of finding efficiencies across the business. I highlighted one of the earlier ones with respect to orthopedics. But we're quite frankly doing that across the entire MedTech portfolio at this point in time, looking for opportunities whether it be aided by artificial intelligence or just infrastructure overall as to how we can further improve the MedTech profitability profile. Right now, we stand a little bit above the middle of the pack in terms of our peer set on margin, and we're looking to get towards the upper end of that peer set.

Thank you. Our next question today is coming from Geoff Meacham from Bank of America. Your line is now live.

Great. Thanks so much for the question. I just wanted to ask you about the XARELTO patient mix that you guys called out. Just help us with kind of current dynamics and maybe looking forward whether this trend you expect to continue? Thank you.

Yeah, Geoff. I can answer that one. So specifically on XARELTO in the quarter, we would say there's two items. It's patient mix, but there is also a one-time entry. Moving forward in 2024, we do expect that there will be a decline but not to the extent that you saw in Q4.

Thank you. Next question is coming from Danielle Antalffy from UBS. Your line is now live.

Hey. Good morning, everyone. Thanks so much for taking the question. Joe, sorry to harp on the MedTech margin side of things. I appreciate everything you're saying for going forward. But just as we look at Q4 specifically, even adding back Laminar, we're still getting to sort of down 400 basis points year-over-year in the quarter. I was just hoping maybe you could bridge us a little bit more. Is there any component of that is sort of price increases taken in late '22 into '23 rolling off or anything that you would highlight there? Thanks so much.

No, Danielle. I think it's really the inflationary impact, so out of the 9% drop that you saw in Q4, 5 points are really from Laminar. The other balance of 4 points, I would chalk up to the inflationary impact that I spoke of earlier and then the mix component, whereby orthopedics, which is our lowest margin portfolio within the MedTech portfolio overall, performed a little bit better. So there's really nothing magical behind it other than the explanations that were already given on the call. Again, we are looking at cost improvement initiatives, specifically in orthopedics, but across the entire portfolio as we move through 2024. But there’s nothing that happened – maybe this is the best way to state it. There’s nothing that happened in Q4 that has us concerned about our outlook or calls around margin profile or EPS for the balance of this upcoming year.

Thank you. Our next question is coming from David Risinger from Leerink Partners. Your line is now live.

Yes. Thanks very much and thanks for all of the details today. So notwithstanding the recently announced Ambrx acquisition, in recent years, J&J has executed more MedTech M&A than pharma M&A. And I don't mean to belabor the point, I know that you got some specific therapeutic area questions. But could you just comment at a high level on what has held J&J back in pharma M&A in recent years and whether we should expect greater cash deployment to accelerate long-term pharma revenue growth going forward? Thank you.

Thank you, David. M&A and external innovation have been fundamental to our pharmaceutical portfolio growth and transformation. As I mentioned earlier, we approach this without bias towards specific sectors. In pharmaceuticals, we prefer to target assets that are around proof of concept. Generally, this means we focus on smaller deals or different modalities such as collaborations or partnerships. Last year, Johnson & Johnson completed over 50 deals, but only the M&A ones make headlines. We have executed multiple transactions in our pharmaceutical sector to enhance our existing portfolio. Our strategy leans towards transactions that can create more value by leveraging our strengths in clinical development, manufacturing, and commercial reach. Most of the deals in our pharmaceutical segment are earlier stage. Do we look beyond that? Yes, we do, but we mainly see more opportunities to create value at an earlier stage. For instance, this year we completed several less-publicized deals, including one with CNBG, now known as AbelZeta, in CAR-T targeting CD19 and CD20, which we believe could be a leading CAR-T treatment in this area potentially launching within this decade. We also entered another deal in antibody drug conjugates with a Korean company called LegoChem, which received little attention. We are consistently working to identify deals in the pharmaceutical space that allow us to leverage all our capabilities in clinical development, manufacturing, and commercial efforts. This approach has contributed to significant value creation in well-known products like DARZALEX and CARVYKTI, which stem from targeting earlier in the development process.

Thank you, David. We have time for one last question.

Our final question today is coming from Rick Wise from Stifel.

Good morning and thank you. Could you provide more detail on your electrophysiology comments? You had an exceptional quarter, and I assume the new products contributed to this success. Could you elaborate on the negative impact from the China VBP? Looking ahead, we have one PFA device approved in the U.S., with another expected within the next month or three. How should we assess the EP franchise as we approach 2024? What factors are you considering in your outlook? Thank you.

Thank you for the question. We achieved strong results in our electrophysiology franchise in 2023, and we anticipate another successful year in 2024 with continued growth. The growth drivers in 2023 were broad, impacting regions such as Asia-Pacific, the U.S., and EMEA. This growth was fueled by procedure recovery, new product performance, and a minor offset from value-based procurement in China. We introduced several new products this year, including the engine generator and our mapping catheters, OCTARAY and OPTRELL. Notably, our QDOT MICRO Catheter for radio frequency ablation has demonstrated efficacy results that surpass any PFA catheter. Our robust commercial execution and extensive clinical support contributed to these outcomes, resulting in a 25% growth in electrophysiology globally in the fourth quarter, with 22% growth in the U.S. and 29% growth outside the U.S. We are confident in our leadership in electrophysiology, backed by 20 years of expertise in the field. Our cardiac ablation strategy includes various approaches, with the CARTO mapping system being a fundamental pillar that enhances procedural efficiency while minimizing fluoroscopy workflow. It is crucial for electrophysiologists to have real-time feedback on heart anatomy, and our CARTO system provides important parameters such as tissue proximity and contact force measurement, which help in assessing the durability of ablation. From the outset, all our catheter offerings will be fully integrated with the CARTO system. We have 5,000 CARTO systems in use worldwide and a strong support network for electrophysiologists. Regarding our catheter development, we are creating a comprehensive portfolio, including VARIPULSE, our multi-electrode catheter recently approved in Japan. We are also working on focal and large focal catheters, and a single-shot catheter, allowing electrophysiologists to select the best option for their specific needs. We have five active clinical trials, with three completed, and have submitted our VARIPULSE catheter for CE Mark, planning to submit it to the U.S. FDA in 2024. While PFA offers a valuable option, radiofrequency ablation remains a staple in our offerings. We believe that the combination of CARTO's procedural efficiency and our dual energy catheter will enable electrophysiologists to adapt to varying anatomies during procedures. I am optimistic about our growth in 2024 and the future of our ablation business. Atrial fibrillation continues to be an under-treated area, and both radiofrequency and PFA ablation show significant improvements in patient outcomes compared to medical therapy. Therefore, I have a positive outlook on the strength and prospects of our atrial fibrillation business.

Thank you, Rick, and thanks to everyone for your questions and your continued interest in our company. We apologize to those we couldn’t get to because of time, but don’t hesitate to reach out to the Investor Relations team with any remaining questions you may have. I will now turn the call back over to Joaquin for some brief closing remarks.

Thank you, Jess. The strong performance we delivered in ‘23 gives me great confidence in the trajectory of our business. As I said earlier, we are entering 2024 from a position of strength, and we have multiple catalysts for growth. No other company is as well positioned as Johnson & Johnson to lead the next wave of healthcare innovation. We look forward to sharing our progress in the year ahead. Thank you.

Thank you. This concludes today's Johnson & Johnson's fourth quarter 2023 earnings conference call. You may now disconnect.